Yellowstone Holding
VC Fund
Versoix, Switzerland
Yellowstone Holding is a VC fund in Versoix focused on Medical and Health Care. Yellowstone Holding promoting new innovative products or technologies from Switzerland to the Asia market via our strong connections.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Yellowstone Holding invests in
Stages Yellowstone Holding invests in
Countries Yellowstone Holding invests in
Round sizes
Round size
- Series A
- $2.7M–$16M
- Series B
- $4M–$11M
Investment Focus
Industry
- Medical 5 (63%)
- Health Care 3 (38%)
- Biotechnology 3 (38%)
- Manufacturing 3 (38%)
- Medical Device 2 (25%)
Stage
- Series A 3 (38%)
- Series B 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- Switzerland 4 (50%)
- Taiwan 1 (13%)
- Germany 1 (13%)
- Portugal 1 (13%)
- United States 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CryoTherapeutics
|
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $10.8M / Series B / Apr 02, 2024 | |
ZuriMED Technologies AG
|
ZuriMED is an innovative team specialized in orthopedic biomechanics and biomaterials.They originated in and are currently based at the Laboratory for Orthopedic Biomechanics at the University Hospital Balgrist – one of the leading Orthopedic clinics in Switzerland.The ZuriMED team has been inventing and developing orthopedic implants since2009. They have developed, rigorously tested, and patented three fully featured devices (BTB Conversion Kit™, EndoCLIP™, ZuriACL™). | $16.2M / Series A / Jul 04, 2023 | |
NU-RISE
|
NU-RISE LDA helping doctors provide better cancer treatment. They have developed a probe that goes inside the body. This probe will monitor, in real-time, the level of radiation the patient is receiving. The Doctor can target the cancer but avoid the healthy organs. Better, safer and more accurate radiation - it's an evolution for cancertreatment. | $3.5M / Seed / Mar 04, 2023 | |
Medyria
|
Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland. | $4M / Series B / Jan 10, 2023 | |
Hyprevention
|
Hycom develops, manufactures, and sells implantable medical devices. | $4.5M / Venture - Series Unknown / Mar 02, 2022 | |
Calciscon
|
Calciscon is a Swiss diagnostic company. Calciscon's aim is to become the leading company for the assessment, prevention and treatment of biomineralization-related medical problems. | $2.7M / Series A / Apr 14, 2021 | |
Hukui Bio
|
Founded in November 2013, HuKui Bio provides total solution and value-added services to global medical devices customers. By focusing on medical electronics and handheld devices for digital healthcare and telemedicine, we do the designing and development in Taiwan, manufacturing in Asia, and delivering our sales & services globally. Combiningseasoned experts and investors from biomedical, tech, and financial industries, we strive to be the best partner in the Asia-Pacific region for MedTech developers, startups and corporates by completing projects on-time, on-budget and by meeting global quality standards concurrently. Our US company, HuKui Tech, is a subsidiary based in the Bay area, 100% owned by HuKui Bio since 2020. | $5.5M / Series C / Jan 12, 2021 | |
Cutiss
|
CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $8.5M / Series A / Jun 26, 2018 |
Co-Investors
GED Ventures Portugal
2 deals together
Zürcher Kantonal Bank
2 deals together
Chindex Medical
1 deal together
Efficient Frontier Investing
1 deal together
InnoMedical
1 deal together
KfW
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Yellowstone Holding invest in?
Yellowstone Holding invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Yellowstone Holding's check size?
Yellowstone Holding typically joins rounds of $2.7M–$16M at Series A and $4M–$11M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Yellowstone Holding participates in.
When did Yellowstone Holding last invest?
The most recent investment recorded for Yellowstone Holding closed in Apr 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
